Tuberculosis Drug Discovery: Issues, Gaps and the Way Forward

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

Volumn , Issue , 2009, Pages 415-440

  Dartois, Véronique ^a   Leong, Franz Joel ^a   Dick, Thomas ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

Antibacterial; Bacteria; Drug discovery; Gaps; Issues; Tuberculosis

Indexed keywords

EID: 70449723600     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626816.ch21     Document Type: Chapter

References (75)

1. Sacchettini, J.C., Rubin, E.J. and Freundlich, J.S. (2008) Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nature Reviews Microbiology, 6, 41-52.
2. Janin, Y.L. (2007) Antituberculosis drugs: ten years of research. Bioorganic and Medicinal Chemistry, 15, 2479-2513.
3. Brennan, P.J., and Young, D.B. (eds) (2008) Handbook of Anti-Tuberculosis Agents, Elsevier, http://intl.elsevierhealth.com/journals/tube.
4. Shah, N.S., Wright, A., Bai, G.H., Barrera, L., Boulahbal, F., Martin-Casabona, N., Drobniewski, F. et al. (2007) Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infectious Diseases, 13, 380-387.
5. Pepper, D.J., Meintjes, G.A., McIlleron, H. and Wilkinson, R.J. (2007) Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discovery Today, 12, 980-989.
6. Goldman, R.C., Plumley, K.V. and Laughon, B.E. (2007) The evolutionofextensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infectious Disorders-Drug Targets, 7, 73-91.
7. WHO (2008) Anti-Tuberculosis Drug Resistance in the World. Fourth Global Report. Drug Resistance Surveillance, 2002-2007. The WHO/IUATLD Global Project on Anti-tuberculosis, Geneva.
8. Dick, T., Dartois, V., Keller, T. and Matter, A. (2008) TB drug discovery from target identification to proof of concept studies, in Handbook of Tuberculosis (eds H. Kaufmann and P. van Helden), Wiley-VCH, Weinheim, pp. 39-159.
9. Payne, D.J., Gwynn, M.N., Holmes, D.J. and Pompliano, D.L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews. Drug Discovery, 6, 29-40.
10. Bakker, B.M., Westerhoff, H.V., Opperdoes, F.R. and Michels, R.A. (2000) Metabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs. Molecular and Biochemical Parasitology, 106, 1-10.
11. Walsh, C. (2003) Validatedtargets andmajor antibiotic classes Antibiotics: Actions, Origins, Resistance, ASM Press, Washington, D.C., pp. 11-88.
12. Lange, R.P., Locher, H.H., Wyss, P.C. and Then, R.L. (2007) The targets of currently used antibacterial agents: lessons for drug discovery. Current Pharmaceutical Design, 13, 3140-3154.
13. Silver, L.L. (2007) Multi-targeting by monotherapeutic antibacterials. Nature Reviews. Drug Discovery, 6, 41-55.
14. Kohanski, M.A., Dwyer, D.J., Hayete, B., Lawrence, C.A. and Collins, J.J. (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell, 130, 797-810.
15. Terstappen, G.C., Schlupen, C., Raggiaschi, R. and Gaviraghi, G. (2007) Target deconvolution strategies in drug discovery. Nature Reviews. Drug Discovery, 6, 891-903.
16. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J. et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 307, 223-227.
17. Manjunatha, U.H., Boshoff, H., Dowd, C.S., Zhang, L., Albert, T.J., Norton, J.E., Daniels, L. 3rd et al. (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 103, 431-436.
18. Connolly, L.E., Edelstein, P.H. and Ramakrishnan, L. (2007) Why is long-term therapy required to cure tuberculosis? PLoS Medicine, 4, e120.
19. Steenken, W. and Pratt, P. (1949) Streptomycin in experimental tuberculosis; effect on the pathogenesis of early tuberculosis in the guinea pig infected with streptomycin-sensitive H37 Rv tubercle bacilli. American Review of Tuberculosis, 59, 664-673.
20. Karlson, A. and Feldman, W. (1949) The effect of combined therapy with streptomycin and para-aminosalicylic acid on experimental tuberculosis in guinea pigs. Mayo Clinic Proceedings, 24, 510-515.
21. Hobby, G., Regna, P. and Lenert, T. (1949) The chemotherapeutic action of streptomycin paraaminosalicylate in experimental tuberculosis in mice. American Review of Tuberculosis, 60, 808-810.
22. Joules, F. and Nassau, E. (1949) Para-aminosalicylic acid; a clinical trial in 10 patients with pulmonary tuberculosis. Tubercle, 30, 98-102.
23. Tempel, C., Hughes, F., Mardis, R., Towbin, M. and Dye, W. (1950) Combined intermittent regimens employing streptomycin and para-aminosalicylic acid in the treatment of pulmonary tuberculosis. Transactions of the Annual Meeting of the National Tuberculosis Association, 46, 27-43.
24. Lucchesi, M. and Mancini, P. (1970) Antimycobacterial activity of rifampicin. Antibiotics and Chemotherapy, 16, 431-443.
25. Arathoon, E.G., Hamilton, J.R., Hench, C.E. and Stevens, D.A. (1990) Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrobial Agents and Chemotherapy, 34, 1655-1659.
26. Chambers, H. (2004) Infectious Diseases: Bacterial and Chlamydial, in Current Medical Diagnosis and Treatment, 43rd edn (eds L. Tierney, S. McPhee and M. Papdakis), The McGraw-Hill Companies, pp. 1337-1379.
27. El-Zammar, O.A. and Katzenstein, A.L. (2007) Pathological diagnosis of granulomatous lung disease: a review. Histopathology, 50, 289-310.
28. Katzenstein, A.-L.A. (1997) INFECTION II. Granulomatous Infections, in Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease, 3rd edn (ed. A-.L.A. Katzenstein), Saunders.
29. Russell, D.G. (2007) Who puts the tubercle in tuberculosis? Nature Reviews Microbiology, 5, 39-47.
30. Cardona, P.J. (2007) New insights on the nature of latent tuberculosis infection and its treatment. Inflammation & Allergy-Drug Targets, 6, 27-39.
31. Flynn, J.L. (2004) Mutual attraction: does it benefit the host or the bug? Nature Immunology, 5, 778-779.
32. Fukunaga, H., Murakami, T., Gondo, T., Sugi, K. and Ishihara, T. (2002) Sensitivity of acid-fast staining for Mycobacterium tuberculosis in formalin-fixed tissue. American Journal of Respiratory and Critical Care Medicine, 166, 994-997.
33. Ulbright, T.M. and Katzenstein, A.L. (1980) Solitary necrotizing granulomas of the lung: differentiating features and etiology. The American Journal of Surgical Pathology, 4, 13-28.
34. Tang, Y.W., Procop, G.W., Zheng, X., Myers, J.L. and Roberts, G.D. (1998) Histologic parameters predictive of mycobacterial infection. American Journal of Clinical Pathology, 109, 331-334.
35. Hernandez-Pando, R., Jeyanathan, M., Mengistu, G., Aguilar, D., Orozco, H., Harboe, M., Rook, G.A. and Bjune, G. (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet, 356, 2133-2138.
36. Ulrichs, T. and Kaufmann, S.H. (2006) New insights into the function of granulomas in human tuberculosis. The Journal of Pathology, 208, 261-269.
37. Stewart, G.R., Robertson, B.D. and Young, D.B. (2003) Tuberculosis: a problem with persistence. Nature Reviews Microbiology, 1, 97-105.
38. Gomez, J.E. and McKinney, J.D. (2004) M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinburgh, Scotland), 84, 29-44.
39. Duncan, K. and Barry, C.E. 3rd (2004) Prospects for new antitubercular drugs. Current Opinion in Microbiology, 7, 460-465.
40. Wayne, L.G. and Sohaskey, C.D. (2001) Nonreplicating persistence of mycobacterium tuberculosis. Annual Review of Microbiology, 55, 139-163.
41. Dhar, N. and McKinney, J.D. (2007) Microbial phenotypic heterogeneity and antibiotic tolerance. Current Opinion in Microbiology, 10, 30-38.
42. Rothstein, D.M., Farquhar, R.S., Sirokman, K., Sondergaard, K.L., Hazlett, C., Doye, A.A., Gwathmey, J.K. et al. (2006) Efficacy of novel rifamycin derivatives against rifamycin-sensitive and-resistant Staphylococcus aureus isolates in murine models of infection. Antimicrobial Agents and Chemotherapy, 50, 3658-3664.
43. Hoogeterp, J.J., Mattie, H., Krul, A.M. and van Furth, R. (1988) The efficacy of rifampicin against Staphylococcus aureus in vitro and in an experimental infection in normal and granulocytopenic mice. Scandinavian Journal of Infectious Diseases, 20, 649-656.
44. Niederweis, M. (2003) Mycobacterial porins-new channel proteins in unique outer membranes. Molecular Microbiology, 49, 1167-1177.
45. Sharbati-Tehrani, S., Meister, B., Appel, B. and Lewin, A. (2004) The porin MspA from Mycobacterium smegmatis improves growth of Mycobacterium bovis BCG. International Journal of Medical Microbiology, 294, 235-245.
46. Mailaender, C., Reiling, N., Engelhardt, H., Bossmann, S., Ehlers, S. and Niederweis, M. (2004) The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. Microbiology (Reading, England), 150, 853-864.
47. Molle, V., Saint, N., Campagna, S., Kremer, L., Lea, E., Draper, P. and Molle, G. (2006) pH-dependent pore-forming activity of OmpATb from Mycobacterium tuberculosis and characterization of the channel by peptidic dissection. Molecular Microbiology, 61, 826-837.
48. Lambert, H.P. (1978) Clinical significance of tissue penetration of antibiotics in the respiratory tract. Scandinavian Journal of Infection and Disease, Suppl, 1978, 262-266.
49. Sauermann, R., Karch, R., Langenberger, H., Kettenbach, J., Mayer-Helm, B., Petsch, M., Wagner, C. et al. (2005) Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrobial Agents and Chemotherapy, 49, 4448-4454.
50. Barclay, W.R., Ebert, R.H., Le Roy, G.V., Manthei, R.W. and Roth, L.J. (1953) Distribution and excretion of radioactive isoniazid in tuberculous patients. Journal of the American Medical Association, 151, 1384-1388.
51. Kislitsyna, N.A. and Kotova, N.I. (1980) Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations. Problemy Tuberkuleza (Moskva), 1980, 63-65.
52. Kiss, I.J., Farago, E., Juhaz, I., Bacsa, S. and Fabian, E. (1976) Investigation on the serum and lung tissue level ofrifampicin in man. International Journal of Clinical Pharmacology and Biopharmacy, 13, 42-47.
53. Hutschala, D., Skhirtladze, K., Zuckermann, A., Wisser, W., Jaksch, P., Mayer-Helm, B.X., Burgmann, H. et al. (2005) In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrobial Agents and Chemotherapy, 49, 5107-5111.
54. Watanabe, A., Anzai, Y., Niitsuma, K., Saito, M., Yanase, K. and Nakamura, M. (2001) Penetration of minocycline hydrochloride into lung tissue and sputum. Chemotherapy, 47, 1-9.
55. Di Paolo, A., Barbara, C., Chella, A., Angeletti, C.A. and Del Tacca, M. (2002) Pharmacokinetics ofazithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacological Research, 46, 545-550.
56. Murdoch, M.B. and Peterson, L.R. (1991) Antimicrobial penetration into polymorphonuclear leukocytes and alveolar macrophages. Seminars in Respiratory Infections, 6, 112-121.
57. Lakshminarayana, B., Patra, A., Nandi, V. and Jayaram, R. (2008) The volume of distribution and lung partitioning are not predictive of efficacy of anti-mycobacterial drugs in the murine aerosol infection model of tuberculosis. Antimicrobial Agents and Chemotherapy, (in press).
58. Brunner, M., Derendorf, H. and Muller, M. (2005) Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Current Opinion in Pharmacology, 5, 495-499.
59. Zeitlinger, M., Muller, M. and Joukhadar, C. (2005) Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS Journal, 7, E600-E608.
60. Tyvold, S.S., Solligard, E., Lyng, O., Steinshamn, S.L., Gunnes, S. and Aadahl, P. (2007) Continuous monitoring of the bronchial epithelial lining fluid by microdialysis. Respiratory Research, 8, 78.
61. Chaurasia, C.S., Muller, M., Bashaw, E.D., Benfeldt, E., Bolinder, J., Bullock, R., Bungay, P.M. et al. (2007) AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. Journal of Clinical Pharmacology, 47, 589-603.
62. Langer, O., Karch, R., Muller, U., Dobrozemsky, G., Abrahim, A., Zeitlinger, M., Lackner, E. et al. (2005) Combined PET and microdialysis for in vivo assessmentof intracellular drug pharmacokinetics in humans. Journal of Nuclear Medicine, 46, 1835-1841.
63. Rubakhin, S.S., Jurchen, J.C., Monroe, E.B. and Sweedler, J.V. (2005) Imaging mass spectrometry: fundamentals and applications to drug discovery. Drug Discovery Today, 10, 823-837.
64. Stoeckli, M., Chaurand, P., Hallahan, D.E. and Caprioli, R.M. (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nature Medicine, 7, 493-496.
65. Altelaar, A.F., Luxembourg, S.L., McDonnell, L.A., Piersma, S.R. and Heeren, R.M. (2007) Imaging mass spectrometry at cellular length scales. Nature Protocols, 2, 1185-1196.
66. Drexler, D.M., Garrett, T.J., Cantone, J.L., Diters, R.W., Mitroka, J.G., Prieto Conaway, M.C., Adams, S.P. et al. (2007) Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. Journal of Pharmacological and Toxicological Methods, 55, 279-288.
67. Sever, J.L. and Youmans, G.P. (1957) The relation of oxygen tension to virulence of tubercle bacilli and to acquired resistance in tuberculosis. The Journal of Infectious Diseases, 101, 193-202.
68. Wayne, L.G. (1960) The bacteriology of respected tuberculous pulmonary lesions. 2. Observations on bacilli which are stainable but which cannot be cultured. The American Review of Respiratory Disease, 82, 370-377.
69. Wayne, L.G. and Lin, K.Y. (1982) Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infection and Immunity, 37, 1042-1049.
70. Aly, S., Wagner, K., Keller, C., Malm, S., Malzan, A., Brandau, S., Bange, F.-C. and Ehlers, S. (2006) Oxygen status oflung granulomas in Mycobacterium tuberculosis-infected mice. The Journal of Pathology, 210, 298-305.
71. Via, L.E., Lin, P.L., Ray, S.M., Carrillo, J., Allen, S.S., Eum, S.Y., Taylor, K. 3rd et al. (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infection and Immunity, 76, 2333-2340.
72. Wayne, L.G. (1976) Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. The American Review of Respiratory Disease, 114, 807-811.
73. Wayne, L.G. (1977) Synchronized replication of Mycobacterium tuberculosis. Infection and Immunity, 17, 528-530.
74. Wayne, L.G. and Hayes, L.G. (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infection and Immunity, 64, 2062-2069.
75. Wayne, L.G. and Sramek, H.A. (1994) Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 38, 2054-2058.